PET and brain tumor image fusion.

PET imaging with (18)F-2-deoxy-2-fluoro-D-glucose (FDG-PET) is useful both for the initial evaluation of brain tumors and for follow up after therapy. Over 400 FDG-PET studies are performed at Duke University Medical Center annually for brain tumors. Image registration of FDG-PET data with anatomic imaging (MRI) is essential to accurately localize the abnormality in the brain because of the metabolic heterogeneity of brain tumors and the high background metabolism of normal cerebral cortex. A practical semi-automated image registration technique has been developed which is used routinely for all brain tumor patients. In the future, image registration will likely become increasingly important for FDG and other PET tracers used for brain tumor imaging, and the combined functional/anatomic information will be utilized directly for therapeutic radiation and surgical treatment planning.

[1]  R. Coleman,et al.  Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  S. Goldman,et al.  PET in stereotactic conditions increases the diagnostic yield of brain biopsy. , 1994, Stereotactic and functional neurosurgery.

[3]  J. Mazziotta,et al.  MRI‐PET Registration with Automated Algorithm , 1993, Journal of computer assisted tomography.

[4]  G Di Chiro,et al.  Prediction of survival in glioma patients by means of positron emission tomography. , 1985, Journal of neurosurgery.

[5]  T. Turkington,et al.  Accuracy of registration of PET, SPECT and MR images of a brain phantom. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  Serge Goldman,et al.  Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  Thomas Czech,et al.  Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  G. Chiro.  Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. , 1987 .

[9]  N. Hata,et al.  An integrated visualization system for surgical planning and guidance using image fusion and an open MR , 2001, Journal of magnetic resonance imaging : JMRI.

[10]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[11]  R. Brooks,et al.  Glycolytic rate (PET) and contrast enhancement (CT) in human cerebral gliomas. , 1983, AJNR. American journal of neuroradiology.

[12]  Abass Alavi,et al.  Positron emission tomography in patients with glioma a predictor of prognosis , 1988, Cancer.

[13]  C. Pelizzari,et al.  Accurate Three‐Dimensional Registration of CT, PET, and/or MR Images of the Brain , 1989, Journal of computer assisted tomography.

[14]  R. Maciunas,et al.  Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. , 1995, Radiology.

[15]  T. Turkington,et al.  Accuracy of Surface Fit Registration for PET and MR Brain Images Using Full and Incomplete Brain Surfaces , 1995, Journal of computer assisted tomography.

[16]  Acnp Snm Task Force on Clinical Pet.  Positron Emission Tomography: Clinical Status in the United States in 1987 , 1988 .

[17]  R Kikinis,et al.  Computer-based imaging and interventional MRI: applications for neurosurgery. , 1999, Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society.

[18]  D. Hwang,et al.  Prediction of Pathology and Survival by FDG PET in Gliomas , 2003, Journal of Neuro-Oncology.